Compare Ginkgo Bioworks Holdings Inc (DNA) vs Norfolk Southern Corporation (NSC) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.21, down 3.99% on the day, reflecting a bearish technical trend. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous labs and contract research. Despite beating EPS estimates in two of the last three quarters, it remains deeply unprofitable with a net income margin of -219.6% in 2025. Analyst sentiment is mixed with a 45% buy rating, but institutional selling and negative cash flows highlight significant challenges.

The outlook is cautious. While the pivot to new business lines offers long-term potential, near-term execution risks and persistent losses pose substantial downside. Investors face high volatility amid uncertain revenue growth and cash burn, requiring careful risk assessment against any speculative recovery thesis.

Norfolk Southern (NSC) trades at $335.41, up 0.24% with neutral technical signals. The company shows strong fundamentals with three consecutive earnings beats and a 21.02% net income margin. Recent Q2 2026 results exceeded expectations with $3.52 EPS versus $3.32 estimate, driven by record revenue and volume growth. The pending $85 billion merger with Union Pacific remains a key development, with both companies filing supplemental information to regulators in July 2026.

NSC presents a mixed outlook with strong operational performance offset by premium valuation concerns. The consensus price target of $369.67 suggests 10% upside potential, but high P/E of 28.62 and declining cash flow trends warrant caution. Key risks include merger regulatory approval, fuel cost pressures, and potential efficiency challenges from rapid traffic growth.